Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment

International Journal of Clinical Practice

Volumn 62, Issue 7, 2008, Pages 1070-1075

  Xu, G ^a   Zhang, H ^a   Zhang, S ^a   Fan, X ^a   Liu, X ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD CLOTTING; COGNITIVE DEFECT; DEMENTIA; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPERFIBRINOGENEMIA; LINEAR REGRESSION ANALYSIS; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCREENING;

EID: 44849095467     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01268.x     Document Type: Article

References (40)

1. Reinhart WH. Fibrinogen-marker or mediator of vascular disease? Vasc Med 2003 8 : 211 6.
2. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984 311 : 501 5.
3. Danesh J, Lewington S, Thompson SG et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005 294 : 1799 809.
4. Stott DJ, Spilg E, Campbell AM et al. Haemostasis in ischaemic stroke and vascular dementia. Blood Coagul Fibrinolysis 2001 12 : 651 7.
5. Andreotti F, Burzotta F, Maseri A. Fibrinogen as a marker of inflammation: a clinical view. Blood Coagul Fibrinolysis 1999 10 (Suppl. 1 S3 4.
6. McGeer PL, McGeer EG. Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 2001 22 : 799 809.
7. Mangiafico RA, Sarnataro F, Mangiafico M, Fiore CE. Impaired cognitive performance in asymptomatic peripheral arterial disease: relation to C-reactive protein and d-dimer levels. Age Ageing 2006 35 : 60 5.
8. Gunstad J, Bausserman L, Paul RH et al. C-reactive protein, but not homocysteine, is related to cognitive dysfunction in older adults with cardiovascular disease. J Clin Neurosci 2006 13 : 540 6.
9. van Oijen M, Witteman JC, Hofman A et al. Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke 2005 36 : 2637 41.
10. Dik MG, Jonker C, Hack CE et al. Serum inflammatory proteins and cognitive decline in older persons. Neurology 2005 64 : 1371 7.
11. Fischer P, Zehetmayer S, Bauer K et al. Relation between vascular risk factors and cognition at age 75. Acta Neurol Scand 2006 114 : 84 90.
12. Piguet O, Grayson DA, Creasey H et al. Vascular risk factors, cognition and dementia incidence over 6 years in the Sydney Older Persons Study. Neuroepidemiology 2003 22 : 165 71.
13. Gauthier S, Reisberg B, Zaudig M et al. Mild cognitive impairment. Lancet 2006 367 : 1262 70.
14. Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 1993 269 : 2386 91.
15. Xu G, Meyer JS, Huang Y et al. Adapting Mini-Mental State Examination for dementia screening among illiterate or minimally educated elderly Chinese. Int J Geriatr Psychiatry 2003 18 : 609 16.
16. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960 23 : 56 62.
17. American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC : American Psychiatric Association, 1994.
18. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984 34 : 939 44.
19. Roman GC, Tatemichi TK, Erkinjuntti T et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993 43 : 250 60.
20. Petersen RC, Smith GE, Ivnik RJ et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995 273 : 1274 8.
21. Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 2005 62 : 1160 3.
22. Boyle PA, Wilson RS, Aggarwal NT et al. Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology 2006 67 : 441 5.
23. Stec JJ, Silbershatz H, Tofler GH et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 2000 102 : 1634 8.
24. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987 258 : 1183 6.
25. Turaj W, Slowik A, Dziedzic T et al. Increased plasma fibrinogen predicts one-year mortality in patients with acute ischemic stroke. J Neurol Sci 2006 246 : 13 9.
26. Von Willebrand factor, P-selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcome. Platelets 1998 9 : 155 9.
27. Eidelman RS, Hennekens CH. Fibrinogen: a predictor of stroke and marker of atherosclerosis. Eur Heart J 2003 24 : 499 500.
28. Tribouilloy C, Peltier M, Colas L et al. Fibrinogen is an independent marker for thoracic aortic atherosclerosis. Am J Cardiol 1998 81 : 321 136.
29. Ding J, Nieto FJ, Beauchamp NJ et al. A prospective analysis of risk factors for white matter disease in the brain stem: the Cardiovascular Health Study. Neuroepidemiology 2003 22 : 275 82.
30. Marti-Fabregas J, Valencia C, Pujol J et al. Fibrinogen and the amount of leukoaraiosis in patients with symptomatic small-vessel disease. Eur Neurol 2002 48 : 185 90.
31. Kario K, Matsuo T, Kobayashi H et al. 'Silent' cerebral infarction is associated with hypercoagulability, endothelial cell damage, and high Lp(a) levels in elderly Japanese. Arterioscler Thromb Vasc Biol 1996 16 : 734 41.
32. Claus JJ, Breteler MM, Hasan D et al. Vascular risk factors, atherosclerosis, cerebral white matter lesions and cerebral perfusion in a population-based study. Eur J Nucl Med 1996 23 : 675 82.
33. Walzl B, Walzl M, Valetitsch H, Lechner H. Increased cerebral perfusion following reduction of fibrinogen and lipid fractions. Haemostasis 1995 25 : 137 43.
34. Parnetti L, Mari D, Mecocci P, Senin U. Pathogenetic mechanisms in vascular dementia. Int J Clin Lab Res 1994 24 : 15 22.
35. Roman GC. Vascular dementia prevention: a risk factor analysis. Cerebrovasc Dis 2005 20 (Suppl. 2 91 100.
36. Gupta A, Pansari K. The association between blood coagulation markers, atherothrombosis and dementia. Int J Clin Pract 2003 57 : 107 11.
37. Gupta A, Watkins A, Thomas P et al. Coagulation and inflammatory markers in Alzheimer's and vascular dementia. Int J Clin Pract 2005 59 : 52 7.
38. Borroni B, Volpi R, Martini G et al. Peripheral blood abnormalities in Alzheimer disease: evidence for early endothelial dysfunction. Alzheimer Dis Assoc Disord 2002 16 : 150 5.
39. Sherman DG, Atkinson RP, Chippendale T et al. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA 2000 283 : 2395 403.
40. Gusev EI, Skvortsova VI, Suslina ZA et al. Batroxobin in patients with ischemic stroke in the carotid system (the multicenter study). Zh Nevrol Psikhiatr Im S S Korsakova 2006 106 : 31 4.